Skip to main content

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Heart and Vascular Center
Professor of Medicine, Harvard Medical School
Boston, USA

Related Videos

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?

Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?

Can you discuss the importance of the two principal PSCK9 CV outcome trials—ODYSSEY Outcomes and FOURIER—and how they are similar and in what ways they are different? What are the implications for the patient with T2D and ASCVD?

Can you discuss the importance of the two principal PSCK9 CV outcome trials—ODYSSEY Outcomes and FOURIER—and how they are similar and in what ways they are different? What are the implications for the patient with T2D and ASCVD?